Blog
RSS FeedPosted by Michael Wonder on 05 Dec 2024
Clearing dense drug patent thickets
27 November 2024 - Proposed reforms from the US Patent and Trademark Office and Congress could work in tandem to prevent ...
Posted by Michael Wonder on 20 May 2024
Patent portfolios protecting 10 top selling prescription drugs
13 May 2024 - In this cross-sectional study of 1429 patents and patent applications protecting the 10 highest revenue brand name ...
Posted by Michael Wonder on 15 Dec 2023
Biologic patent thickets and terminal disclaimers
14 December 2023 - Spending on biologics in 2021 represented $260 billion or 46% of all spending on prescription drugs in ...
Posted by Michael Wonder on 07 Dec 2023
Biden Administration could seize patents for high priced drugs
7 December 2023 - The Biden administration proposed a rule Thursday that could let the Government seize patents for medicines developed ...
Posted by Michael Wonder on 14 Nov 2023
Inequitable conduct and invalidation of patents related to FDA regulated products
13 November 2023 - Median brand name drug launch prices increased from $2,115 in 2008 to $180,007 in 2021. ...
Posted by Michael Wonder on 14 Nov 2023
Ancillary product patents to extend biologic patent life
13 November 2023 - In 2021, 46% ($260 billion) of all gross prescription drug spending in the US was on biologic ...
Posted by Michael Wonder on 04 Oct 2023
US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic
2 October 2023 - A US Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo ...
Posted by Michael Wonder on 02 Aug 2023
Changes in the number of continuation patents on drugs approved by the FDA
1 August 2023 - Brand name pharmaceutical manufacturers often sustain high prices in the US by obtaining patents that delay generic ...
Posted by Michael Wonder on 29 Jun 2023
Commonwealth loses appeal in clopidogrel PBS damages undertaking case: important lessons for patentees and generics alike
27 June 2023 - Commonwealth claims on the damages undertaking remain a live issue for patentees and generics to consider. ...
Posted by Michael Wonder on 09 Mar 2023
Patent system key to lower drug prices, experts say
9 March 2023 - Following the Biden administration’s progress towards lowering prescription drug prices with Medicare price negotiations, some industry ...
Posted by Michael Wonder on 29 Jan 2023
How a drug company made $114 billion by gaming the US patent system
28 January 2023 - AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. ...
Posted by Michael Wonder on 26 Jan 2023
Patent reform and lower drug prices should be bipartisan priorities
25 January 2023 - As the 118th Congress convenes this month in Washington D.C., many pundits and advocates have little ...
Posted by Michael Wonder on 18 Jan 2023
Medunik Canada obtains new Notice of Compliance from Health Canada for Ruzurgi (amifampridine) following a favourable Canadian Federal Court of Appeal ruling
17 January 2023 - Medunik Canada is pleased to announce that on 9 January 2023, the Federal Court of Appeal of ...
Posted by Michael Wonder on 13 Jan 2023
Recent patent reform bills and their implications for prescription drugs
13 January 2022 - In 2022, several bills were introduced in Congress to revamp US intellectual property law. ...
Posted by Michael Wonder on 07 Dec 2022
US backs delay to decision on COVID patent waiver extension
6 December 2022 - The United States on Tuesday urged delaying a decision on whether to waive patent protection for ...